With Ebola affecting a vast population in West Africa, there is some good news from GlaxoSmithKline plc (ADR) (NYSE:GSK) as it has successfully tested its Ebola Vaccine on Monkeys.

The test included monkeys with Ebola infection and after giving the experimental drug, the monkey didn’t develop any signs of the deadly virus. As per the findings of the experiment, the scientists have already started human trials to test the effectiveness of this medicine and its ability to strengthen the human immune system against the virus. World Health organization has released a statement that upon the successful completion of the test, the potential cure will be available within a month. Ebola virus has caused more than 2,000 deaths in West Africa.

GlaxoSmithKline plc (ADR) (NYSE:GSK)’s vaccine helped all the animals included in the study to survive the virus whereas the unprotected ones died within six days. According to Anthony Fauci, National Institute of Health, said that the primary purpose of this medical study “is to determine if it is safe, and if it induces a response that you would predict would be protective.”

Some additional drugs for the prevention as well as cure of the disease are being tried at different medical institutions. ZMapp is a potential treatment, developed by Mapp Biopharmaceutical Inc, which helped two Americans improve against the virus. French National health institute, Inserm, is seeking permission for human trials from Guinea health authorities.

GlaxoSmithKline plc (ADR) (NYSE:GSK) is a biopharmaceutical company with a market cap of $114.63 billion and dividend/yield of 5.54%. GlaxoSmithKline plc (ADR) (NYSE:GSK) reported net turnover of £5.6 billion with core earnings per share of 19.1 GBP. The company reported dividend of 19p for the second quarter 2014.

This article has been written by Prakash Pandey.